A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer Comorbid With Type 2 Diabetes
Type 2 diabetes may cause severe complications such as nephropathy and retinopathy.
Additionally, it is associated with increased risk for cardiovascular events and diseases.
Surgical intervention with gastric bypass has been shown to attenuate glycemic levels in
obese patient comorbid with type 2 diabetes. However, since gastric bypass is not a standard
procedure, surgical protocol including stomach and small intestine reconstruction may be
varied. The investigators and others have found that stomach and small intestine
reconstruction may affect the efficacy of diabetic treatment. In this study, the
investigators will compare the efficacy of Billroth II and Roux en Y reconstruction on
glycemic control in stomach cancer patients with type 2 diabetes. Both Billroth II and Roux
en Y are used in stomach-small intestine reconstruction after subtotal gastrectomy. No
differences in postoperative outcomes and quality of life have been reported in Billroth II
and Roux en Y reconstruction.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Fasting and postprandial glycemic levels, HbA1C Number of anti-diabetic drugs Dosage of anti-diabetic drugs
1 year after surgery
Yu Wang, M.D
Dongfang Hospital, Xiamen University
China: Ministry of Health